Metagenomi(MGX) - 2025 Q4 - Annual Results

Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non- human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application ("IND") in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for ...